The RealLine EGFR 7R Kit is detecting and differentiating following mutations:
- Deletions and complex mutations in exon 19
- G719X – detected but not genotyped G719S, G719A, G719C
Non-small cell lung cancer (NSCLC) is the most common type of the lung cancer. Activating somatic mutations within the tyrosin kinase (TK) domain in the epidermal growth factor receptor (EGFR) protein are associated with sensitivity of tumors to EGFR-TK inhibitors. So patients with tumors harboring either of these mutant forms of EGFR are extremely sensitive to the selective EGFR-tyrosine kinase (TK) inhibitors like Gefitinib, Erlotinib or other anti-EGFR-therapy.